Inclusion Criteria:

1. Persons over the age of 18 with full capacity for civil conduct;

2. The subject voluntarily agrees to participate in the study and signs the informed
consent, and can provide valid identification, understand and comply with the
requirements of the study protocol;

3. Fertile male and female subjects of reproductive age agreed to use effective
contraceptive measures from the beginning of the study to 2 months after full
vaccination.

Exclusion Criteria:

1. Suspected or confirmed fever within 72 hours before enrollment, or armpit
temperature ≥37.3℃ on the day of enrollment;

2. Have a history of severe allergy to any component of the test vaccine, including
aluminum preparation, such as anaphylactic shock, allergic laryngeal edema, allergic
purpura, thrombocytopenic purpura, dyspnea, angiopantic edema, etc.; Or have a
history of severe adverse reactions to any of the above mentioned vaccines or
medications;

3. people who currently have or have a history of COVID-19;

4. Persons suffering from the following diseases:

① have thrombocytopenia, any coagulation dysfunction or receive anticoagulant
treatment, etc.;

② Congenital or acquired immune deficiency or autoimmune disease history or received
immunomodulatory treatment within 6 months Treatment, such as immunosuppressive
doses of glucocorticoid (dose reference: equivalent to prednisone 20mg/ day, more
than one weeks); Or monoclonal antibodies; Or thymosin; Or interferon; However,
topical application (e.g. ointments, eye drops) is allowed Liquid, inhalant or nasal
spray);

③ Have been diagnosed with a known infectious disease, such as active tuberculosis,
viral hepatitis, human immunodeficiency virus or treponema pallidum;

④ Neurological disorders (e.g., convulsions, migraines, epilepsy, stroke, epileptic
seizures in the last three years, encephalopathy, focal neurological deficits,
Guillain-Barre syndrome, encephalomyelitis or transverse myelitis); History of
mental illness or family history;

⑤ functional absence of spleen, and absence of spleen or splenectomy caused by any
reason;

⑥ There are serious chronic diseases or diseases in the progressive stage can not be
controlled smoothly, such as diabetes, drugs can not control Hypertension (systolic
blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg);

⑦ Severe liver and kidney diseases; Any current respiratory illness requiring
routine medication (e.g., chronic obstructive pulmonary disease [COPD], asthma) or
any exacerbation of respiratory illness (e.g., exacerbation of asthma) within the
last 5 years; A history of serious cardiovascular disease (e.g., congestive heart
failure, cardiomyopathy, ischemic heart disease, arrhythmia, conduction block,
myocardial infarction, pulmonary heart disease) or myocarditis or pericarditis;

⑧ Cancer patients (except basal cell carcinoma).

5. had taken an antipyretic or painkiller within 24 hours before the first dose of
vaccine;

6. Those who have received novel coronavirus vaccine, or subunit vaccine and/or
inactivated vaccine within 7 days before the first dose, or live attenuated vaccine
within 14 days;

7. Have received blood or blood-related products, including immunoglobulin, within 3
months; Or planned for use during the study period;

8. Lactating or pregnant women (including women of childbearing age who have positive
urine pregnancy test), or women who plan to have a pregnancy within 2 months after
full vaccination of the test vaccine or their partners;

9. Have participated in or are currently participating in other COVID-19 related
clinical trials;

10. The Investigator believes that the subject has any disease or condition that may
place the subject at unacceptable risk; Subjects cannot meet the requirements of the
program; Conditions that interfere with the assessment of vaccine response.